You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥AH齊漲 外媒稱中國計劃於7月批准德國BioNTech研發的新冠疫苗在國內使用
格隆匯 04-19 11:11
格隆匯4月19日丨復星醫藥(02196.HK)漲4.38%,報38.1港元;復星醫藥(600196.SH)更是大漲6.78%。據華爾街日報,中國計劃於7月批准德國BioNTech SE研發的新型冠狀病毒疫苗。 若獲批,這將成為中國批准的首個外國新冠疫苗。中國官員正在審查該疫苗的臨牀試驗數據,預計將在未來10周內批准在國內使用。去年8月,這家德國製藥商宣佈與上海復星醫藥集團有限公司達成一項合作意向協議,在獲批後向香港和澳門供應1,000萬劑這款疫苗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account